TIDMMXC

RNS Number : 0694F

MGC Pharmaceuticals Limited

13 July 2021

Expiry of Share Options and Appendix 3H

13 July 2021

ASX, LSE Code: MXC

MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the Company') wishes to advise that 10,000,000 Share Options on issue expired on 30 June 2021.

Further information can be found here

-Ends-

Authorised for release by David Lim, Company Secretary, for further information, please contact:

 
 MGC Pharmaceuticals Ltd         PR/IR Advisors - Media & Capital 
  Roby Zomer                      Partners 
  CEO & Managing Director         Rod Hinchcliffe (IR) +61 412 
  +61 8 6382 3390                 277 377 
  info@mgcpharma.com.au           Rod.Hinchcliffe@mcpartners.com.au 
 UK Broker - Turner Pope         UK PR Advisors - Tavistock 
  Andy Thacker                    Charles Vivian +44 207 920 
  Andy.Thacker@TurnerPope.com     3150 
  Zoe Alexander +44 20 3657       Charles.Vivian@tavistock.co.uk 
  0050                            Tim Pearson +44 7983 118 502 
  Zoe.Alexander@TurnerPope.com    Tim.Pearson@tavistock.co.uk 
 

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels :

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFIFEADLIVLIL

(END) Dow Jones Newswires

July 13, 2021 05:52 ET (09:52 GMT)

Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Jul 2024 to Aug 2024 Click Here for more Mgc Pharmaceuticals Charts.
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Aug 2023 to Aug 2024 Click Here for more Mgc Pharmaceuticals Charts.